1
|
Babin HG, Ritzmann J, Bart N, Schmidt M, Kruck T, Zhai L, Löbl MC, Nguyen GN, Spinnler C, Ranasinghe L, Warburton RJ, Heyn C, Wieck AD, Ludwig A. Charge Tunable GaAs Quantum Dots in a Photonic n-i-p Diode. Nanomaterials (Basel) 2021; 11:2703. [PMID: 34685139 PMCID: PMC8537184 DOI: 10.3390/nano11102703] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Revised: 10/06/2021] [Accepted: 10/11/2021] [Indexed: 12/03/2022]
Abstract
In this submission, we discuss the growth of charge-controllable GaAs quantum dots embedded in an n-i-p diode structure, from the perspective of a molecular beam epitaxy grower. The QDs show no blinking and narrow linewidths. We show that the parameters used led to a bimodal growth mode of QDs resulting from low arsenic surface coverage. We identify one of the modes as that showing good properties found in previous work. As the morphology of the fabricated QDs does not hint at outstanding properties, we attribute the good performance of this sample to the low impurity levels in the matrix material and the ability of n- and p-doped contact regions to stabilize the charge state. We present the challenges met in characterizing the sample with ensemble photoluminescence spectroscopy caused by the photonic structure used. We show two straightforward methods to overcome this hurdle and gain insight into QD emission properties.
Collapse
Affiliation(s)
- Hans Georg Babin
- Lehrstuhl für Angewandte Festkörperphysik, Ruhr-Universität Bochum, Universitätsstraße 150, DE-44801 Bochum, Germany; (J.R.); (N.B.); (M.S.); (T.K.); (A.D.W.); (A.L.)
| | - Julian Ritzmann
- Lehrstuhl für Angewandte Festkörperphysik, Ruhr-Universität Bochum, Universitätsstraße 150, DE-44801 Bochum, Germany; (J.R.); (N.B.); (M.S.); (T.K.); (A.D.W.); (A.L.)
| | - Nikolai Bart
- Lehrstuhl für Angewandte Festkörperphysik, Ruhr-Universität Bochum, Universitätsstraße 150, DE-44801 Bochum, Germany; (J.R.); (N.B.); (M.S.); (T.K.); (A.D.W.); (A.L.)
| | - Marcel Schmidt
- Lehrstuhl für Angewandte Festkörperphysik, Ruhr-Universität Bochum, Universitätsstraße 150, DE-44801 Bochum, Germany; (J.R.); (N.B.); (M.S.); (T.K.); (A.D.W.); (A.L.)
| | - Timo Kruck
- Lehrstuhl für Angewandte Festkörperphysik, Ruhr-Universität Bochum, Universitätsstraße 150, DE-44801 Bochum, Germany; (J.R.); (N.B.); (M.S.); (T.K.); (A.D.W.); (A.L.)
| | - Liang Zhai
- Department of Physics, University of Basel, CH-4056 Basel, Switzerland; (L.Z.); (M.C.L.); (G.N.N.); (C.S.); (R.J.W.)
| | - Matthias C. Löbl
- Department of Physics, University of Basel, CH-4056 Basel, Switzerland; (L.Z.); (M.C.L.); (G.N.N.); (C.S.); (R.J.W.)
| | - Giang N. Nguyen
- Department of Physics, University of Basel, CH-4056 Basel, Switzerland; (L.Z.); (M.C.L.); (G.N.N.); (C.S.); (R.J.W.)
| | - Clemens Spinnler
- Department of Physics, University of Basel, CH-4056 Basel, Switzerland; (L.Z.); (M.C.L.); (G.N.N.); (C.S.); (R.J.W.)
| | - Leonardo Ranasinghe
- Center for Hybrid Nanostructures (CHyN), University of Hamburg, DE-22761 Hamburg, Germany; (L.R.); (C.H.)
| | - Richard J. Warburton
- Department of Physics, University of Basel, CH-4056 Basel, Switzerland; (L.Z.); (M.C.L.); (G.N.N.); (C.S.); (R.J.W.)
| | - Christian Heyn
- Center for Hybrid Nanostructures (CHyN), University of Hamburg, DE-22761 Hamburg, Germany; (L.R.); (C.H.)
| | - Andreas D. Wieck
- Lehrstuhl für Angewandte Festkörperphysik, Ruhr-Universität Bochum, Universitätsstraße 150, DE-44801 Bochum, Germany; (J.R.); (N.B.); (M.S.); (T.K.); (A.D.W.); (A.L.)
| | - Arne Ludwig
- Lehrstuhl für Angewandte Festkörperphysik, Ruhr-Universität Bochum, Universitätsstraße 150, DE-44801 Bochum, Germany; (J.R.); (N.B.); (M.S.); (T.K.); (A.D.W.); (A.L.)
| |
Collapse
|
2
|
Taylor PDP, Valkiers S, De Bievre P, Flegel U, Kruck T. Stable isotope analysis of iron by gas-phase electron impact mass spectrometry. Anal Chem 2002. [DOI: 10.1021/ac00069a036] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
3
|
Brown DR, Qin K, Herms JW, Madlung A, Manson J, Strome R, Fraser PE, Kruck T, von Bohlen A, Schulz-Schaeffer W, Giese A, Westaway D, Kretzschmar H. The cellular prion protein binds copper in vivo. Nature 1997; 390:684-7. [PMID: 9414160 DOI: 10.1038/37783] [Citation(s) in RCA: 623] [Impact Index Per Article: 23.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The normal cellular form of prion protein (PrPC) is a precursor to the pathogenic protease-resistant forms (PrPSc) believed to cause scrapie, bovine spongiform encephalopathy (BSE) and Creutzfeldt-Jakob disease. Its amino terminus contains the octapeptide PHGGGWGQ, which is repeated four times and is among the best-preserved regions of mammalian PrPC. Here we show that the amino-terminal domain of PrPC exhibits five to six sites that bind copper (Cu(II)) presented as a glycine chelate. At neutral pH, binding occurs with positive cooperativity, with binding affinity compatible with estimates for extracellular, labile copper. Two lines of independently derived PrPC gene-ablated (Prnp0/0) mice exhibit severe reductions in the copper content of membrane-enriched brain extracts and similar reductions in synaptosomal and endosome-enriched subcellular fractions. Prnp0/0 mice also have altered cellular phenotypes, including a reduction in the activity of copper/zinc superoxide dismutase and altered electrophysiological responses in the presence of excess copper. These findings indicate that PrPC can exist in a Cu-metalloprotein form in vivo.
Collapse
Affiliation(s)
- D R Brown
- Department of Neuropathology, Georg-August-Universität Göttingen, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Savory J, Exley C, Forbes WF, Huang Y, Joshi JG, Kruck T, McLachlan DR, Wakayama I. Can the controversy of the role of aluminum in Alzheimer's disease be resolved? What are the suggested approaches to this controversy and methodological issues to be considered? J Toxicol Environ Health 1996; 48:615-35. [PMID: 8772802 DOI: 10.1080/009841096161104] [Citation(s) in RCA: 108] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Aluminum (Al) is unquestionably neurotoxic in both experimental animals and certain human diseases. Minute quantities injected intracerebrally into rabbits will induce severe neurological symptoms and neuropathological features of neurodegeneration. Hyper-aluminemia often develops in patients with renal failure being treated with intermittent hemodialysis on a chronic basis, and in severe cases results in an encephalopathy. Uremic adults and premature infants not on dialysis treatment also can develop encephalopathy due to Al toxicity, as is the case when large amounts of alum are used as a urinary bladder irrigant. There are many other examples of Al-induced neurotoxicity; however, the question as to whether Al presents a health hazard to humans as a contributing factor to Alzheimer's disease is still the subject of debate. Several lines of evidence are presented that have formed the basis of the debate concerning the possible pathogenic role for Al in Alzheimer's disease. Important evidence for an Al-Alzheimer's causal relationship is the observation by laser microprobe mass analysis (LMMS) of the presence of Al in neurofibrillary tangles, although there are conflicting data on the extent of the Al deposition. The relatively poor sensitivity of some of the analytical instruments available for these challenging in situ microanalyses could explain the discrepant results, although LMMS and perhaps secondary ion mass spectrometry (SIMS) appear to be sufficiently sensitive. Harmonization of the techniques is an essential next step. There is new evidence that exposure to Al from drinking water might result in cognitive impairment and an increased incidence of Alzheimer's disease. However, these epidemiological studies have inherent problems that must be scrutinized to determine if an association really does exist. An understanding of a possible enhanced bioavailability of Al in this type of exposure, versus other exposures such as antacid intake or industrial exposure, needs to be considered and explored. There has been one promising clinical trial of the treatment of Alzheimer's disease patients with the Al chelator desferrioxamine (DFO). Further studies are needed, and if confirmation is forthcoming then such data could also support an Al-Alzheimer's disease link as well as suggesting that DFO offers potential as a therapeutic agent. The possibility that iron might be the offending agent needs to be considered since DFO is a very strong iron chelator. The significance of Al-induced neurofibrillary degeneration in experimental animals should be assessed especially in light of new data showing that this model exhibits abnormally phosphorylated tau protein structures in the neuronal perikarya. Thus the key questions that must be answered before it can be asserted that Al possesses causal relationship to Alzheimer's disease, are as follows and are addressed in this present discussion: (1) Are there elevations of the concentration of Al in the brains of Alzheimer's disease patients? (2) Is there a relationship between environmental exposure to Al, particularly in drinking water, and an increased risk of Alzheimer's disease? (3) Is treatment with DFO a potentially useful therapeutic approach and to what extent might beneficial effects of DFO implicate Al in the etiology of Alzheimer's disease? (4) Are there similarities between the experimental animal studies and Alzheimer's disease particularly in the development of abnormal forms of tau seen in neurofibrillary tangles? (5) Does Al promote the deposition of the A beta peptide in Alzheimer's disease? (6) Does hyperaluminemia associated with long-term hemodialysis treatment induce neurofibrillary degeneration? If the answer to each of these six questions is yes, then does this assert that Al possesses a causal relationship to Alzheimer's disease? On the other hand, must all six be met to be able to make this assertion?
Collapse
Affiliation(s)
- J Savory
- Department of Pathology, University of Virginia, Charlottesville, Virginia, USA
| | | | | | | | | | | | | | | |
Collapse
|
5
|
|